The ability to measure SOD1 synthesis and clearance in vivo in humans may provide better understanding of the pathogenesis of SOD1 in sporadic ALS and earlier assessments of target engagement in the setting of ASO or other mRNA‐targeted therapeutics.19 The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.